Determination of urinary 13C-caffeine metabolites by liquid chromatography-mass spectrometry: The use of metabolic ratios to assess CYP1A2 activity

Journal of Pharmaceutical and Biomedical Analysis

Volumn 34, Issue 2, 2004, Pages 379-389

  Caubet, Marie Sophie ^a   Comte, Blandine ^b,c   Brazier, Jean Louis ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Caffeine metabolic ratios; CYP1A2; Labelled caffeine; LC MS

Indexed keywords

CAFFEINE; CARBON 13; CYTOCHROME P450 1A2; CARBON; ISOENZYME;

ARTICLE; ATMOSPHERIC PRESSURE; CONTROLLED STUDY; ELECTROSPRAY; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATHEMATICAL COMPUTING; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; SMOKING; ADOLESCENT; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; ENZYME ACTIVATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METHODOLOGY; NONPARAMETRIC TEST; PHYSIOLOGY; URINE;

ADOLESCENT; ADULT; CAFFEINE; CARBON ISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; ENZYME ACTIVATION; FEMALE; HUMANS; ISOENZYMES; MALE; STATISTICS, NONPARAMETRIC;

EID: 0842330578     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(03)00528-4     Document Type: Article

References (31)

1. Rating D., Langhans C.D. Eur. J. Pediatr. 156(Suppl. 1):1997;S18-S23.
2. Tanaka A., Breimer D.D. J. Clin. Pharm. Ther. 22:1997;237-249.
3. Kalow W., Tang B.K. Clin. Pharmacol. Ther. 53:1993;503-514.
4. Kalow W., Tang B.K. Clin. Pharmacol. Ther. 50:1991;508-519.
5. Tang B.K., Kadar D., Qian L., Iriah J., Yip J., Kalow W. Clin. Pharmacol. Ther. 49:1991;648-657.
6. Visiten K., Poulsen H.E., Loft S. Carcinogenesis. 13:1992;1561-1568.
7. Grant D.M., Tang B.K., Kalow W. Clin. Pharmacol. Ther. 33:1983;591-602.
8. Kalow W., Tang B.K. Clin. Pharmacol. Ther. 49:1991;44-48.
9. Parker A.C., Pritchard P., Preston T., Smyth R.L., Choonara I. Arch. Dis. Child. 77:1997;239-241.
10. Holstege A., Staiger M., Haag K., Gerok W. Klin. Wochenschr. 67:1989;6-15.
11. Schreiber-Deturmeny E., Bruguerolle B. J. Chromatogr. B. 677:1996;305-312.
12. Papadoyannis I.N., Samanidou V.F., Georga K.A. J. Liq. Rel. Technol. 19:1996;2559-2578.
13. Tajerzadeh H., Dadashzadeh S. J. Pharm. Biomed. Anal. 13:1995;1507-1512.
14. Georga K.A., Samanidou V.F., Papadoyannis I.N. J. Liq. Rel. Technol. 22:1999;2975-2990.
15. Caubet M.S., Walid E., Dubuc M.C., Brazier J.L. J. Pharm. Biomed. Anal. 27:2001;261-270.
16. Krul C., Hageman G. J. Chromatogr. B. 709:1998;27-34.
17. Cox P.J., Farmer P.B., Foster A.B., Gilby E.D., Jarman M. Cancer Treat. Rep. 60:1976;483-491.
18. Benchekroun Y., Dautraix S., Desage M., Brazier J.L. Eur. J. Drug Metab. Pharmacokinet. 22:1997;127-133.
19. Benchekroun Y., Dautraix S., Desage M., Brazier J.L. J. Chromatogr. B, Biomed. Sci. Appl. 688:1997;245-254.
20. Brazier J.L., Elbast W. Analysis. 27:1999;218-224.
21. T.R. Browne, in: Stables Isotopes in Pharmaceutical Research, vol. 26, Elsevier, Amsterdam, 1997.
22. Caubet M.S., Laplante A., Caillé J., Brazier J.L. Isotopes Environ. Health Stud. 38:2002;71-77.
23. Fernandez C.A., Des Rosiers C. J. Biol. Chem. 270:1995;10037-10042.
24. Barone J.J., Roberts H.R. Food Chem. Toxicol. 34:1996;119-129.
25. Kanazawa H., Atsumi R., Matsushima Y., Kizu J. J. Chromatogr. A. 870:2000;87-96.
26. Carrillo J.A., Benitez J. Clin. Pharmacol. Ther. 55:1994;293-304.
27. Rostami-Hodjegan A., Nurminen S., Jackson P.R., Tucker G.T. Pharmacogenetics. 6:1996;121-149.
28. Birkett D., Miners J.O. Br. J. Clin. Pharmacol. 31:1991;405-408.
29. Campbell M.E., Spielberg S.P., Kalow W. Clin. Pharmacol. Ther. 42:1987;157-165.
30. Butler M.A., Lang N.P., Young J.F., Caporaso N.E., Vineis P., Hayes R.B., Teitel C.H., Massengill J.P., Lawsen M.F., Kadlubar F.F. Pharmacogenetics. 2:1992;116-127.
31. Relling M.V., Lin J.S., Ayers G.D., Evans W.E. Clin. Pharmacol. Ther. 52:1992;643-658.